Cerebral Venous Sinus Thrombosis Complicating Herpes Zoster Ophthalmicus Ophthalmoplegia
We report the case of a 68-year-old lady with herpes zoster ophthalmicus ophthalmoplegia who developed cerebral venous thrombosis (CVT).PMID:38646240 | PMC:PMC11026991 | DOI:10.7759/cureus.56520 (Source: Herpes)
Source: Herpes - April 22, 2024 Category: Infectious Diseases Authors: Meithem Ali Nonyelum Obiechina Kay Teck Ling Angela Nandi Bhaskar Mukherjee Source Type: research
Serum Dehydroepiandrosterone sulfate (DHEA-S) level and its potential impact on immune responses and symptom severity after Oxford-AstraZeneca COVID-19 vaccination
CONCLUSION: DHEA-S is not involved in the quality of protective immune response during Oxford-AstraZeneca COVID-19 vaccination.PMID:38615381 | DOI:10.1016/j.intimp.2024.112057 (Source: International Immunopharmacology)
Source: International Immunopharmacology - April 14, 2024 Category: Allergy & Immunology Authors: Mitra Abbasifard Maryam Dehghan Banadaki Gholamhossein Taghipour Khaje Sharifi Amir Rahnama Zahra Bagheri-Hosseinabadi Source Type: research
Serum Dehydroepiandrosterone sulfate (DHEA-S) level and its potential impact on immune responses and symptom severity after Oxford-AstraZeneca COVID-19 vaccination
CONCLUSION: DHEA-S is not involved in the quality of protective immune response during Oxford-AstraZeneca COVID-19 vaccination.PMID:38615381 | DOI:10.1016/j.intimp.2024.112057 (Source: International Immunopharmacology)
Source: International Immunopharmacology - April 14, 2024 Category: Allergy & Immunology Authors: Mitra Abbasifard Maryam Dehghan Banadaki Gholamhossein Taghipour Khaje Sharifi Amir Rahnama Zahra Bagheri-Hosseinabadi Source Type: research
Risk of SARS-CoV-2 infection in patients with hematologic diseases receiving tixagevimab/cilgavimab as pre-exposure prophylaxis in most recent Omicron sublineages era
Although the overall mortality during SARS-CoV-2 Omicron variants of concern (VoC) wave might be lower than that seen with other previous VoCs immunocompromised individuals remain at increased the risk of hospitalization and prolonged duration of the infection compared to the general population [1]. Moreover, persons with immunosuppression may experience reduced vaccine immune response with an impaired seroconversion and effectiveness [2]. To address the need to protect these individuals from breakthrough infections and possibly from long-lasting SARS-CoV-2 infections, in December 2021 the combination tixagevimab/cilgavima...
Source: International Journal of Infectious Diseases - April 11, 2024 Category: Infectious Diseases Authors: Alessandra Vergori, Alessandro Cozzi Lepri, Marta Chiuchiarelli, Valentina Mazzotta, Elisabetta Metafuni, Giulia Matusali, Valentina Siciliano, Jessica Paulicelli, Eleonora Alma, Agostina Siniscalchi, Simona Sica, Elisabetta Abruzzese, Massimo Fantoni, An Tags: Short Communication Source Type: research
Detection of SARS-CoV-2-specific mucosal antibodies in saliva following concomitant COVID-19 and influenza vaccination in the ComFluCOV trial
Vaccine. 2024 Apr 4:S0264-410X(24)00367-0. doi: 10.1016/j.vaccine.2024.03.061. Online ahead of print.ABSTRACTThe ComFluCOV trial randomized 679 participants to receive an age-appropriate influenza vaccine, or placebo, alongside their second COVID-19 vaccine. Concomitant administration was shown to be safe, and to preserve systemic immune responses to both vaccines. Here we report on a secondary outcome of the trial investigating SARS-CoV-2-specific mucosal antibody responses. Anti-spike IgG and IgA levels in saliva were measured with in-house ELISAs. Concomitant administration of an influenza vaccine did not affect salivar...
Source: Vaccine - April 5, 2024 Category: Allergy & Immunology Authors: Holly E Baum Russell Thirard Alice Halliday Sarah Baos Amy C Thomas Rosie A Harris Elizabeth Oliver Lucy Culliford Benjamin Hitchings Rachel Todd Kapil Gupta Anu Goenka Adam Finn Chris A Rogers Rajeka Lazarus ComFluCOV Trial Group Source Type: research
Detection of SARS-CoV-2-specific mucosal antibodies in saliva following concomitant COVID-19 and influenza vaccination in the ComFluCOV trial
Vaccine. 2024 Apr 4:S0264-410X(24)00367-0. doi: 10.1016/j.vaccine.2024.03.061. Online ahead of print.ABSTRACTThe ComFluCOV trial randomized 679 participants to receive an age-appropriate influenza vaccine, or placebo, alongside their second COVID-19 vaccine. Concomitant administration was shown to be safe, and to preserve systemic immune responses to both vaccines. Here we report on a secondary outcome of the trial investigating SARS-CoV-2-specific mucosal antibody responses. Anti-spike IgG and IgA levels in saliva were measured with in-house ELISAs. Concomitant administration of an influenza vaccine did not affect salivar...
Source: Vaccine - April 5, 2024 Category: Allergy & Immunology Authors: Holly E Baum Russell Thirard Alice Halliday Sarah Baos Amy C Thomas Rosie A Harris Elizabeth Oliver Lucy Culliford Benjamin Hitchings Rachel Todd Kapil Gupta Anu Goenka Adam Finn Chris A Rogers Rajeka Lazarus ComFluCOV Trial Group Source Type: research
Synthetic lethality: targeting SMARCA2 ATPase in SMARCA4-deficient tumors – a review of patent literature from 2019–30 June 2023
. (Source: Expert Opinion on Therapeutic Patents)
Source: Expert Opinion on Therapeutic Patents - April 5, 2024 Category: Drugs & Pharmacology Authors: Kyle D. ReichlEsther C. Y. LeeAriamala GopalsamyOncology R & D, AstraZeneca, Waltham, MA, USA Source Type: research
Parents and teachers ’ perspectives on a school-located influenza vaccination program: A pilot study in the Region of Murcia, Spain
Volume 20, Issue 1, December 2024 . (Source: Human Vaccines and Immunotherapeutics)
Source: Human Vaccines and Immunotherapeutics - April 4, 2024 Category: Allergy & Immunology Authors: Matilde Zornoza MorenoJaime P érez-MartínMarta Robles Mañuecoa Health Prevention and Protection Service, General Directorate of Public Health and Addictions, Health Council, Region de Murcia, Spainb Immunotherapy and Vaccines Unit, AstraZeneca Farmacé Source Type: research
Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial
Lancet Oncol. 2024 Apr;25(4):439-454. doi: 10.1016/S1470-2045(24)00064-0.ABSTRACTBACKGROUND: DESTINY-Lung01 is a multicentre, open-label, phase 2 study evaluating the antitumour activity and safety of trastuzumab deruxtecan, a HER2-directed antibody-drug conjugate, in patients with HER2-overexpressing or HER2 (ERBB2)-mutant unresectable or metastatic non-small-cell lung cancer (NSCLC). The results of the HER2-mutant cohort (cohort 2) have been reported elsewhere. Herein, we report the primary analysis of cohorts 1 and 1A, which aimed to evaluate the activity and safety of trastuzumab deruxtecan 5·4 mg/kg and 6·4 mg/kg in...
Source: Ann Oncol - March 28, 2024 Category: Cancer & Oncology Authors: Egbert F Smit Enriqueta Felip Dipesh Uprety Misako Nagasaka Kazuhiko Nakagawa Luis Paz-Ares Rodr íguez Jose M Pacheco Bob T Li David Planchard Christina Baik Yasushi Goto Haruyasu Murakami Andreas Saltos Kaline Pereira Ayumi Taguchi Yingkai Cheng Qi Yan Source Type: research
Danicopan: First Approval
This article summarizes the milestones in the development of danicopan leading to this first approval for PNH. (Source: Drugs)
Source: Drugs - March 26, 2024 Category: Drugs & Pharmacology Source Type: research
COVID-19 vaccine reactogenicity among participants enrolled in the GENCOV study
CONCLUSIONS: We provide evidence of relatively mild and short-lived reactions reported by participants who have received approved COVID-19 vaccines.PMID:38521677 | DOI:10.1016/j.vaccine.2024.03.030 (Source: Vaccine)
Source: Vaccine - March 23, 2024 Category: Allergy & Immunology Authors: Gregory Morgan Selina Casalino Sunakshi Chowdhary Erika Frangione Chun Yiu Jordan Fung Elisa Lapadula Saranya Arnoldo Erin Bearss Alexandra Binnie Bjug Borgundvaag Laurent Briollais Marc Dagher Luke Devine Steven M Friedman Zeeshan Khan Chloe Mighton Koni Source Type: research
COVID-19 vaccine reactogenicity among participants enrolled in the GENCOV study
CONCLUSIONS: We provide evidence of relatively mild and short-lived reactions reported by participants who have received approved COVID-19 vaccines.PMID:38521677 | DOI:10.1016/j.vaccine.2024.03.030 (Source: Vaccine)
Source: Vaccine - March 23, 2024 Category: Allergy & Immunology Authors: Gregory Morgan Selina Casalino Sunakshi Chowdhary Erika Frangione Chun Yiu Jordan Fung Elisa Lapadula Saranya Arnoldo Erin Bearss Alexandra Binnie Bjug Borgundvaag Laurent Briollais Marc Dagher Luke Devine Steven M Friedman Zeeshan Khan Chloe Mighton Koni Source Type: research
Cell immunity to SARS-CoV-2 after natural infection and/or different vaccination regimens
ConclusionHeterologous vaccination (AZ/PZ) elicited the strongest immunity among the two-dose vaccination regimens. The immunity offered by the third-booster dose of SARS-CoV-2 vaccine depends not only on the type of vaccine administered but also on previous doses and prior infection. Previous exposure to SARS-CoV-2 antigens by infection strongly affect immunity of vaccinated individuals. (Source: Frontiers in cellular and infection microbiology)
Source: Frontiers in cellular and infection microbiology - March 20, 2024 Category: Microbiology Source Type: research
Immunogenicity and adverse events of the COVID-19 vaccines in healthy and individuals with autoimmune diseases in an Iranian population
Conclusion: Our findings revealed that the Sinopharm and Oxford-AstraZeneca vaccines are effective in the production of neutralizing antibodies in healthy subjects and patients with autoimmune disorders undergoing immunosuppressive therapies without considerable reactogenicity.PMID:38494849 | PMC:PMC10946076 | DOI:10.1177/03946320241239202 (Source: International Journal of Immunopathology and Pharmacology)
Source: International Journal of Immunopathology and Pharmacology - March 18, 2024 Category: Allergy & Immunology Authors: Amin Moradi Hasan-Abad Mohsen Arbabi Hamidreza Gilasi Hossein Motedayyen Source Type: research
